Meeting Banner
Abstract #3390

QSM and T2* Mapping in a Six Month Placebo-Controlled Clinical Trial of the Iron Chelator Deferiprone in Parkinson’s Disease

Rexford Newbould1, Courtney Bishop1, Antonio Martin-Bastida2, and David Dexter2

1Imanova Centre for Imaging Sciences, London, United Kingdom, 2Imperial College London, London, United Kingdom

A double-blind placebo-controlled clinical trial of an iron chelation therapy was performed in 25 subjects with Parkinson’s disease (PD) and 12 healthy matched controls. Two MRI measures of brain iron at each of three visits at baseline, 3 months, and 6 months were derived from a high resolution 3D multiecho volume: T2* and QSM maps. T2* values significantly lengthened in six of nine pre-defined ROIs by the final visit in the highest dose group. QSM values , however, did not change with treatment. This differential trajectory between relaxation and susceptibility may result from ferritin’s complex relaxation behavior.

This abstract and the presentation materials are available to members only; a login is required.

Join Here